APA (7th ed.) Citation

Ku, G., Shen, L., Klempner, S., Pan, H., Kratz, J., Liang, X., . . . Zhu, A. (2023). 1039P First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors. Annals of Oncology, 34, S631. https://doi.org/10.1016/j.annonc.2023.09.2178

Chicago Style (17th ed.) Citation

Ku, G., et al. "1039P First-in-human Phase I Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody in Advanced Solid Tumors." Annals of Oncology 34 (2023): S631. https://doi.org/10.1016/j.annonc.2023.09.2178.

MLA (9th ed.) Citation

Ku, G., et al. "1039P First-in-human Phase I Study of Givastomig, a Novel Claudin 18.2/4-1BB Bispecific Antibody in Advanced Solid Tumors." Annals of Oncology, vol. 34, 2023, p. S631, https://doi.org/10.1016/j.annonc.2023.09.2178.